What is Inscopix?
Inscopix is at the forefront of addressing challenging brain disorders through advanced therapeutic development. The company provides validated solutions for real-time neural activity mapping within brain circuits. These objective, quantitative assays are crucial for generating unprecedented insights into disease mechanisms. Inscopix's technology has demonstrated superior accuracy in predicting clinical efficacy compared to traditional animal behavior models when assessing a therapeutic candidate's ability to restore normal brain function. Their discoveries are instrumental in decoding the brain, deepening the understanding of drug mechanisms of action, and enabling more effective drug screening.
How much funding has Inscopix raised?
Inscopix has raised a total of $11M across 2 funding rounds:
Series A
$10M
Debt
$1M
Series A (2016): $10M with participation from Floodgate Fund, Playground, and AME Cloud Ventures
Debt (2020): $1M led by PPP
Key Investors in Inscopix
Floodgate Fund
Floodgate Fund is a venture capital firm specializing in early-stage technology investments, focusing on supporting extraordinary founders at the pre-seed and seed stages with pattern-breaking innovative companies.
Playground
Playground Global invests in founders leveraging frontier technologies to build transformational businesses with multi-generational impact, offering expertise across AI, automation, life sciences, and beyond.
AME Cloud Ventures
AME Cloud Ventures, led by Yahoo! co-founder Jerry Yang, focuses on seed to later-stage companies building data infrastructure and value chains, supporting entrepreneurs with operational experience and a strong network.
What's next for Inscopix?
The recent major strategic investment signifies a pivotal moment for Inscopix, likely enabling the company to accelerate its research and development pipelines, expand its scientific team, and further validate its predictive preclinical therapeutic development platform. This infusion of capital, within the context of major enterprise-level funding, suggests Inscopix is poised for significant scaling and potentially moving towards later-stage clinical trials. The company's focus on objective, quantitative brain assays positions it to overcome historic challenges in the field and catalyze breakthroughs in treating difficult-to-treat brain disorders.
See full Inscopix company page
